Objective: Studies in adults indicate that ampicillin, in a dose-dependent manner, impairs platelet function and moderately prolongs the bleeding time (generally by 60 to 90 s). Unlike aspirin, the inhibition induced by ampicillin involves both reversible and irreversible mechanisms and is not observed immediately after initial dosing (generally requiring approximately 24 h). Ampicillin is administered commonly to neonatal intensive care unit (NICU) patients, but its effect on bleeding time in this population has not been reported earlier.
Introduction
Forming an effective platelet plug is an essential part of hemostasis, but certain medications including aspirin and other non-steroidal anti-inflammatories can impair this process. [1] [2] [3] Ampicillin is one of the antibiotics best known to damage platelet function 4-9 but we are unaware of any studies of this effect of ampicillin in neonates.
The capacity of neonates to generate a hemostatically effective platelet plug can be assessed by in vivo methods (neonatal template bleeding time) and by in vitro methods (platelet function analyzer (PFA)-100 times). 1,10 -18 We obtained these tests before and at intervals after the first, second, third or fourth dose of ampicillin given to neonatal intensive care unit (NICU) patients.
Methods
Patients in the NICU of the McKay-Dee Hospital Center, Ogden, UT, USA were deemed eligible to participate in this study if the neonatologist ordered, during the first 2 days after birth, intravenous ampicillin in the unit dose range of 50 to 100 mg kg -1 body weight, dosed every 12 h (100 to 200 mg kg -1 day -1 ). Patients were considered ineligible if they had a platelet count <100 000 ml -1 or if they had petechiae or any bleeding problem. A cranial ultrasound examination was not required before study entry.
The platelet count, mean platelet volume and hematocrit were measured electronically (Coulter LH 750 Hematology Analyzer, Beckman Coulter, Fullerton, CA, USA). A template bleeding time was performed (by MJS or RDC) using methods described earlier. 1, [10] [11] [12] The before and after ampicillin bleeding time pairs were always performed by the same technician. Briefly, a bloodpressure cuff appropriate for the infant's size was placed on an upper extremity and set at a pressure equal to the last measured mean blood pressure. If no mean blood pressure had been recorded in the previous 6 h, the pressure was set at 20 mm Hg for those with a weight <1 kg, at 25 mm Hg for those weighing 1 to 2 kg, and at 30 mm Hg for those weighing >2 kg. The volar surface of the forearm was then cleaned with alcohol and air dried. The template device (Surgicutt Newborn, International Technidyne Corporation, Edison, NJ, USA) was activated, and thereafter blood was absorbed from the incision site using the Surgicutt Newborn filter paper, every 15 s until the bleeding stopped. The number of seconds between the incision and the cessation of bleeding was read as the bleeding time.
The Intermountain Healthcare Clinical Hematology Laboratory performed the PFA-100 using the manufacture's recommendations (Dade Schering, Miami, FL, USA). Samples were drawn from a central line when available, otherwise by venipuncture. Only the epinephrine cartridge (not the adenosine diphosphate cartridge) was used to limit the study phlebotomy losses. To maintain the recommended ratio of blood to citrate (9:1), 80 ml of citrate were removed from each blood collection tube (BD Diagnostics, Franklin Lakes, NJ, USA) using a micropipetter (Finnpipettte, Thermo Fisher Scientific, Waltham, MA, USA). This permitted the test sample to be 0.9 ml rather than 1.8 ml. As two PFA-100 tests were performed on each patient (one before and one after ampicillin) eliminating the adenosine diphosphate cartridge resulted in 1.8 ml less blood than would otherwise be needed. 1 Groups of patients were to receive the studies 2 to 6 h after the first dose of ampicillin, 8 to 12 h after the third dose or 8 to 12 h after the fourth dose of ampicillin. Descriptive statistics were calculated using Statit (Corvallis, OR, USA). Means and s.d. were used to express values in groups that were normally distributed. A paired t-test was used to assess differences in pre-dosing versus post-dosing values in each study subject. Statistical significance was set as P<0.05. The Institutional Review Board of the Intermountain Healthcare approved the study protocol, and parents of the participants signed an informed consent document.
Results
During the 5 months the study was open for enrollment (February 2009 to June 2009) 170 patients were admitted to the NICU, of which 92 were treated with intravenous ampicillin. In 35 of these 92, the mothers had received antipartum ampicillin or penicillin and these neonates were excluded from study participation because transplacentally acquired antibiotics might confound the platelet function studies. Of the remaining 57 neonates, one was ineligible on the basis of a platelet count <100 000 ml -1 . From the remaining 56, parents of 21 were contacted by the research staff and given study information. Parents of the other 35 eligible patients were not contacted, on the basis of unavailability of an individual (MJS or RDC) to perform the template bleeding time studies. Of the 21 cases in which parents were contacted, 3 declined study participation and the remaining 18 gave written informed consent. All 18 were entered into the study protocol. However, one was withdrawn from the study by the mother before completing the testing and two were transferred to the local children's hospital for a surgical problem before the post-ampicillin tests were obtained. Thus, 15 patients completed the study.
The 15 study patients, at birth, ranged from 33 to 41 weeks gestation and weighed 1760 to 3835 g. None had clinical bleeding problems noted during the days they received ampicillin dosing. The pre-dosing platelet counts, mean platelet volume measurements, number of doses of ampicillin administered and days of mechanical ventilation are shown in the Table 1 . None of the 15 had positive cultures, none had ampicillin dosing continued beyond 7 days and none had mechanical ventilation beyond 3 days. All 15 were treated with gentamicin as well as ampicillin.
All template bleeding times were successful, but two of the PFA-100 tests failed because of microclots in the blood sample. Before the first ampicillin dose was given the template bleeding times (Figure 1 ) averaged 134 s (95% confidence interval (CI), 120 to 148 s). In all, 2 to 6 h after the first dose of ampicillin no prolongation in bleeding times were observed, but after the third and fourth doses the bleeding times were longer by an average of 60 s (95% CI, 37 to 83 s, P<0.001). Before the first dose of ampicillin was given the PFA-100 times averaged 123 s (95% CI, 96 to 149 s). After the first and second ampicillin doses no prolongation was observed, but after the third and fourth doses the PFA-100 times were longer by an average of 20 s (95% CI, À20 to 60 s, P ¼ 0.15). All nine with a bleeding time performed after the third or fourth dose of ampicillin had a longer bleeding time than before the first dose. Platelet counts after the third or fourth dose of ampicillin were slightly higher than before the first dose of ampicillin (before first dose; 275 000 ml -1 , 95% CI, 226 300 to 325 900 ml -1 versus after third or fourth dose 290 000 ml -1 , 95% CI, 239 400 to 341 500 ml -1 , P ¼ 0.04). In total, 10 of the patients were treated with an ampicillin dose of 100 mg kg -1 every 12 h and 5 with 50 mg kg -1 every 12 h (Table 1) , at the discretion of the ordering clinician. Insufficient data were available to assess the effect of dose on bleeding time. No correlation was observed between bleeding time, or PFA-100 times, and platelet count or mean platelet volume.
Discussion
Producing an effective platelet plug is an important component of hemostasis. Medications such as clopidogrel were developed to inhibit platelet function and thereby prevent thrombotic complications. 19 However, other medications inhibit platelet function not as a desired effect but as an unwanted effect. For example, non-selective non-steroidal anti-inflammatories such as naproxen prolong the bleeding time, which can lead to complications such as gastrointestinal hemorrhage. [20] [21] [22] Ampicillin is one of the antibiotics best known to have antiplatelet effects. [4] [5] [6] [7] [8] [9] Ampicillin administration is relatively common in the NICU, but its effect on platelet function in NICU patients has not been reported. We assessed platelet function before and after ampicillin dosing, using the template bleeding time and the PFA-100 times. The peak serum level of ampicillin in the blood is expected just after intravenous dosing, and the half-life in neonates is approximately 5 h. 23, 24 However, the adverse effect of ampicillin on platelet function appears not to be temporally related to its peak serum concentration, but is a cumulative effect. 4, 7, 9 Thus, to cover a wide range of possibilities, we obtained platelet function studies at intervals ranging from 2 h after the first dose to 12 h after the fourth dose.
Ampicillin impairs platelet function by reversibly and irreversibly interfering with receptor binding. 4, 9 The impairment is not significant immediately; in vitro studies require approximately 24 h of incubation to show the effect. Similarly, in vitro studies require approximately 24 h after dosing to impair platelet function. [4] [5] [6] This period may be needed for intercalation of the ampicillin molecule into the platelet membrane lipid bilayer, producing interference with binding of various agonists to receptors.
We are aware of several pitfalls in our study. First, this was not a placebo-controlled study in which some received ampicillin and others received placebo. We dismissed such a design on the basis of ethical concerns because ampicillin was invariably ordered for a clinical reason. However, lack of a placebo renders our data unable to exclude the possibility that 2 or 3 days after admission to the NICU, neonates develop a prolonged bleeding time unrelated to ampicillin. We highly doubt this possibility, on the basis that the opposite has been reported; namely, bleeding times shorten over the first week after birth. [11] [12] [13] [14] A second limitation in our study is the small numbers of patients studied, and the variability of gestational ages among the study subjects. Third, there is welldescribed operator variability in the bleeding time test. To minimize this problem we had only two technicians (MJS and RDC) perform all of the tests. Indeed, the range in template bleeding times we obtained was no greater than the range in PFA-100 times. Fourth, all 15 neonates were receiving medications other than ampicillin. Although ampicillin is the only medication, of those they were receiving, to have a known anti-platelet effect, it remains possible that combinations with other medications or conditions contributed to their prolongation in bleeding time. The bleeding times we measured in this study were shorter than those we reported in a recent study of ibuprofen lysine. 1 In fact, the longer bleeding times we observed after three or four doses of ampicillin were similar to the pre-ibuprofen bleeding times we reported earlier. This apparent discrepancy might be because all neonates in our ibuprofen study had already received several doses of ampicillin, and thus they already had some degree of platelet impairment before the ibuprofen doses were begun. We speculate that the anti-platelet effect of ampicillin explains, at least in part, the discrepancy between relatively short PFA-100 times reported from umbilical cord blood and the longer times reported from NICU patients during the first days after birth. 16, 18 On the basis of our present studies, and similar findings in adults, we conclude that ampicillin administered to neonates can indeed moderately prolong their bleeding time. However, any clinically significant bleeding tendency conveyed to NICU patients by ampicillin requires much more definition. For instance, a 60 s prolongation in bleeding time might be clinically trivial in most neonates, but perhaps in some patients it could be problematic. The NICU patients we studied were all at low risk for hemorrhagic problems; all were X33 weeks gestation, and all were culture negative, with 3 days or fewer of mechanical ventilation. We speculate that neonates at high risk for hemorrhage, such as extremely low birth weight (<1000 g) neonates, those on extracorporeal membrane oxygenation or undergoing surgery, or those with thrombocytopenia, might indeed have a higher bleeding risk on the basis of ampicillin administration. We suggest that more study is needed to quantify the effect of ampicillin on bleeding in such patients, to define any dose-effect relationships, and to define any additive effects on bleeding tendency when ampicillin is used along with other medications or treatments that have anti-platelet effects, such as nitric oxide 25, 26 or indomethacin. 23, 24 
